Ascelia Pharma AB (publ) (STO:ACE)

Ascelia Pharma AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Selling, General & Admin	16.06	17.31	17.33	30.21	29.56	30.32
Research & Development	55.31	56.82	50.8	81.27	118.11	107.57
Other Operating Expenses	-0.4	-0	-	-0	-	-
Operating Expenses	70.97	74.13	68.12	111.48	147.67	137.9
Operating Income	-70.97	-74.13	-68.12	-111.48	-147.67	-137.9
Interest Expense	-	-1.7	-3.71	-	-0.05	-0.08
Interest & Investment Income	0.79	0.81	0.77	1.32	0.64	0.01
Currency Exchange Gain (Loss)	-1.49	-1.49	0.54	0.55	13.93	8.44
Other Non Operating Income (Expenses)	-0.22	-0.22	-9.61	-	-0	-
EBT Excluding Unusual Items	-71.88	-76.72	-80.12	-109.61	-133.16	-129.52
Pretax Income	-71.88	-76.72	-80.12	-109.61	-133.16	-129.52
Income Tax Expense	-0.98	-0.47	-0.09	-0.32	-1.93	-3.62
Net Income	-70.9	-76.25	-80.03	-109.29	-131.22	-125.9
Net Income to Common	-70.9	-76.25	-80.03	-109.29	-131.22	-125.9
Shares Outstanding (Basic)	121	113	54	34	35	33
Shares Outstanding (Diluted)	121	113	54	34	35	33
Shares Change (YoY)	74.07%	110.07%	60.15%	-3.10%	5.58%	25.46%
EPS (Basic)	-0.59	-0.67	-1.48	-3.24	-3.77	-3.82
EPS (Diluted)	-0.59	-0.67	-1.48	-3.24	-3.77	-3.82
Free Cash Flow	-71.25	-72.31	-62.84	-126.79	-125.26	-116.6
Free Cash Flow Per Share	-0.59	-0.64	-1.16	-3.76	-3.60	-3.54
EBITDA	-70.96	-74.11	-68.05	-111.4	-147.6	-137.8
D&A For EBITDA	0.01	0.02	0.07	0.07	0.07	0.1
EBIT	-70.97	-74.13	-68.12	-111.48	-147.67	-137.9

Source: S&P Global Market Intelligence. Standard template. Financial Sources.